Published in

Wiley, Experimental Dermatology, 3(23), p. 202-204, 2014

DOI: 10.1111/exd.12336

Links

Tools

Export citation

Search in Google Scholar

Increased frequencies of CD11b(+)CD33(+)CD14(+)HLA-DRlow myeloid-derived suppressor cells are an early event in melanoma patients

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population characterized by immunosuppressive activity. Elevated levels of MDSC in peripheral blood are found in inflammatory diseases as well as in malignant tumors where they are supposed to be major contributors to mechanisms of tumor-associated tolerance. We investigated the frequency and function of MDSC in peripheral blood of melanoma patients and observed an accumulation of CD11b(+) CD33(+) CD14(+) HLA-DR(low) MDSC in all stages of disease (I-IV), including early stage I patients. Disease progression and enhanced tumor burden did not result in a further increase of frequencies or change in phenotype of MDSC. By investigation of specific MDSC-associated cytokines in patients' sera, we found an accumulation of IL-8 in all stages of disease. T cell suppressor assays revealed that MDSC critically contribute to suppressed antigen-specific T cell reactivity and thus might explain the frequently observed transient effects of immunotherapeutic strategies in melanoma patients. This article is protected by copyright. All rights reserved.